Cargando…
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PC...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311616/ https://www.ncbi.nlm.nih.gov/pubmed/34317250 http://dx.doi.org/10.1016/j.jaccas.2019.09.026 |